Introduction
Mithramycin (Plicamycin, Mithracin, MIT) is a bright yellow, crystalline solid belonging to a group of aureolic acid type of antibiotics; produced naturally by a variety of Streptomyces sp. especially S. argillaceus, S. plicatus and S. tanashiensis [1] [2] [3] . Structurally, it is an aromatic polyketide antibiotic containing aglycon moiety, derived from the series of condensation reactions, catalyzed by a Type II polyketide synthase [4, 5] . It is a known antitumor agent and acts on variety of tumor cell lines [6] [7] [8] . Antitumor properties of mithramycin are attributed to its role in inhibition of DNA dependent RNA synthesis. In the presence of Mg ++ , it cross-links to G+C rich regions of DNA, thereby preventing the binding of Sp (specificity proteins) transcription factors, consequently affecting transcription [9] [10] [11] [12] .
Although majority of work related to mithramycin is concerned with its antitumor properties, it is also known to exhibit activity against Gram positive bacteria [13, 14] . However,
Materials and Methods
The media ingredients such as Beef extract, Malt extract, Peptone, Yeast extract, Corn steep liquor etc. used for cultivation and fermentation of microbes were obtained from Hi Media Laboratories Pvt. Ltd, India. Salts such as NaCl, CaCO 3 NaNO 3 etc were procured from Merck Specialties Pvt. Ltd, India.
The normal phase flash chromatography was performed on CombiFlash R f (Teledyne isco) using Redicep R f 20 g silica column. HPLC analysis and UV spectra were monitored on Shimadzu LC-2010-PDA instrument (Shimadzu, Kyoto, Japan). The data were processed with LC-solution software (Shimadzu, Kyoto, Japan). Distilled LR grade solvents were used for column chromatography and TLC, HPLC grade solvents from Merck were used for preparative and analytical HPLC. TLC Silica gel 60 F 254 plates were from Merck Specialties Pvt. Ltd, India. The NMR spectra were recorded on Bruker Avance at 500 MHz.
Sample collection, isolation and fermentation of the organism
Soil samples were collected from playa region of Pokhran (26.92°N 71.92°E), a remote region surrounded by rocky, sandy hills and salt lakes, located in Jaisalmer district in Thar Desert of Rajasthan state in India. The playa is a flat barren land in desert like areas with few shrubs and salt depositions seen intermittently. Pokhran playa is approximately 12 sq Km area of semi-arid loose sandy soil characterized with high concentrations of halite and traces of calcite, gypsum, proto-dolomite and anhydrite as a result of low rainfall and high evaporation to precipitation rate. The genetic identity and novelty of microbial extremophiles (i.e., bacteria, archaea, and protists) of this area remains largely unexplored [29] . The surface soil samples were collected with a sterile spatula and stored in sterile polythene containers. These samples were stored at ambient temperature and processed for microbial isolation at research centre of Piramal Enterprises Ltd., Mumbai, India.
Approximately 0.5 g of the collected sandy soil was suspended in 5 ml sterile saline (8.5 g/l NaCl in demineralised water) and vortexed for 1 min. This was diluted serially 1:10 up to 10 . 200 µl of 10 -3 dilution of the soil suspension was surface spread on modified Bennet's agar medium containing (g/l), Glucose 10, Casamino acids 2, Yeast Extract 2, Beef Extract 2, Agar powder 15, final pH 7.2-7.5, supplemented with 50 g/l NaCl. The plates were incubated at 25 ± 1°C for 2-3 weeks and observed regularly for appearance of actinomycetes colonies. The producer strain of the mithramycin was one such isolate. The isolate was picked up, purified and maintained on modified ISP2 medium slants containing (g/l), Glucose 40, Yeast extract 40, Malt extract 100, Agar powder 15, final pH 7.5, supplemented with 50 g/l NaCl. The isolate was designated with code PM1129877.
A loopful of growth from 15 days old slant of this strain PM1129877 was inoculated in 274 (1) seed medium containing (g/l), Glucose 15, Peptone 7.5, Yeast extract 7.5, Corn steep liquor 5, NaCl 5, CaCO 3 2, pH was adjusted to 7.5. The culture was incubated on shaker at 200 rpm for 72 h at 30°C. 4% (v/v) of seed inoculum was added in 20 L production medium 1M containing (g/l), Glycerol 30, Glucose 3, Peptone 3, Yeast extract 2, CaCO 3 3, NaNO 3 1, NaCl 30, final pH 7.5. The medium was supplemented with 15 g/l additional NaCl. The 200 production medium flasks (each containing 100 ml medium in 1 L capacity flasks) were incubated on shaker at 200 rpm for 96 h at 30°C. After incubation, contents of the flasks were pooled together and representative sample (100 ml) of this whole broth was extracted with equal volume of methanol under shaking condition for 1.5 h at 30°C. The contents were centrifuged and supernatant (Methanolic extract of whole broth, as mentioned in Table 1 ) was screened against Gram positive and Gram negative bacterial test cultures and yeasts and fungal test cultures. Antimicrobial activity was determined by whole cell agar well diffusion bioassay by boring 6 mm diameter wells in agarified medium and adding 50 µl samples to be tested in it [30] . Vancomycin (20 µg/ml), Gentamicin (50 µg/ml) and Amphotericin B (20µg/ml) were used as standard antibiotics for Gram positive bacteria, Gram negative bacteria and fungi respectively. Absolute methanol was used as solvent control.
Isolation, purification and characterization of the active compound 20 L of whole fermented broth was stirred with equal volume of absolute methanol for 1.5 h and the filtrate was concentrated to its half the volume under reduced pressure at 45°C. The concentrate was subjected to HP-20 resin adsorption chromatography and stirred for 1.5 h. Then HP-20 resin was washed with de-mineralised (DM) water and eluted with 80% aqueous methanol followed by absolute methanol. Both methanolic eluates were pooled and concentrated under reduced pressure at 40°C to obtain crude extract. The extract was subjected to normal phase (Silica gel, 100-200 mesh) flash column chromatography and the compounds were eluted by increasing proportion of ethyl acetate in petroleum ether. The fractions were pooled based on the similar silica TLC pattern (Mobile phase; Methanol: CHCI 3 = 1:9) observed at UV 254 nm. The bioactivity data indicated that active components were eluted by 20% ethyl acetate in petroleum ether. The final purification up to 99.5% was achieved by preparative HPLC. The pure compound was analyzed by analytical HPLC {(Column: LiChrospher, RP-18, 125 X 4.6mm, 5µm); Mobile phase: water and acetonitrile, 98/0, 0/15, 0/20, 98/21, 98/25 (% water/time in min)}. The compound was analyzed by LC-ESI MS on Micro QTOF of Bruker Daltonics. DMDO-d6 was used as solvent for these experiments and chemical shifts were referenced to the solvent peak at 2.50 ppm. The UV spectrum was obtained from a HPLC-photodiode array analysis of the compound using 15% acetonitrile/water [31] .
Determination of minimum inhibitory concentration (MIC) values
The potency of purified mithramycin was determined by generating MIC values by the NCCLS (CLSI) macro-broth dilution method for aerobic bacteria M7-A5 [32] . Linezolid was used as a standard compound as it is currently used in clinic as therapeutic agent for MRSA infections. Mithramycin was suitably diluted in the concentration range of 0.0078-16 µg/ml. The concentration range for Linezolid used was 0.019-16 µg/ml. Absolute methanol was used as a solvent for making stock solutions of test compounds. Muller Hinton broth with two fold serial dilution of the compound was inoculated with 10 5 colony forming units/ml of test culture and incubated at 37°C for 24 hr. The visible growth (turbidity visible to naked eyes) was noted from each tube and the MIC values were recorded. The MIC of mithramycin was determined against 45 test organisms which included 37 Gram positive and 8 Gram negative clinical, in house and standard American Type Culture Collection (ATCC) strains. 
Test organisms for bioactivity estimation

Results and Discussion
The organism and its bioactivity
The colony of the producer strain PM1129877; which was picked after 2-3 weeks of incubation was leathery and surrounded by halo of translucent mycelia. It was circular to ovoid, 3-5 mm in diameter, with shining rough surface, convex with pointed tip, having yellow ochre substrate mycelia but devoid of aerial mycelia, sporulation and diffused pigments. On the basis of its morphological features, the organism was identified to be belonging to the genus Streptomyces. The culture (PM1129877) was deposited in Microbial Culture Collection [International Depositary Authority (IDA) at National Centre for Cell Science], Department of Biotechnology, Government of India] Pune, Maharashtra 411021-India.
The sample generated from methanolic whole broth extraction of PM1129877, had yellow color and exhibited exclusive and potent activity against Gram positive test cultures with very slight or no activity against yeasts/fungal and Gram negative test cultures (Table 1) . For bioassay guided isolation of the compound, only Gram positive bacterial test cultures were selected.
Structural determination
The molecular weight of the compound m/z 1084.5 corresponded to the molecular formula C 52 H 76 O 24 of mithramycin ( Table 2 ). The isolated compound (Figure 1 to Figure 4 ) was confirmed as mithramycin by different spectroscopic analysis ( Table 3 and Figure 3 ) such as LC-MS and 1 H NMR data [31, 33, 34] .
Determination of potency of mithramycin by MIC estimation
Mithramycin exhibited potent growth inhibitory activity against Gram positive bacterial strains (Table 4) , especially against clinical, resistant strains of MRSA and VRE. It inhibited the growth of MSSA and MRSA strains of S. aureus in the MIC range of 0.125-0.25 µg/ml with MIC 90 value of 0.25 µg/ml. It also displayed activity against vancomycin resistant and vancomycin sensitive strains of Enterococci exhibiting MIC range of1-16 µg/ ml with MIC 90 value of 2 µg/ml. Clinical strains of Enterococci were inhibited in the MIC range of 1-2 µg/ml with MIC 90 value of 2 µg/ml. Bacillus spp. were also strongly inhibited with MIC range of 0.031-1 µg/ml.
Apart from MIC estimation, mithramycin was also subjected to agar well diffusion assay against 8 Gram negative strains (Table 4) up to 256 µg/ml concentration. There was no zone of inhibition around any agar well for any of these test cultures, indicating mithramycin was ineffective against Gram negative test organisms. These results indicated that perhaps mithramycin was unable to penetrate the outer cell membrane barrier of the Gram negative test organisms and hence exhibited specific in vitro activity against different Gram positive test organisms only.
We started the present study with a hope to find a new antimicrobial compound, from microorganism, isolated from soil collected from untapped natural habitat, such as from playa region. In this journey, although we discovered a known molecule, mithramycin, it exhibited novel bioactivity against MRSA and VRE strains. Mithramycin with brand name Mithracin ® was available in the market and was also FDA approved for the treatment of testicular cancer and for the treatment of hypercalcemia [35] . Despite hepatotoxicity and nephrotoxicity problems and other side effects, recently there has been renewed interest in aureolic acid class of compounds especially mithramycin, pertaining to new uses and activities such as inhibition of apoptosis and antiangiogenic activity [36] . Moreover clinical trials for mithramycin especially in cancer have also been started recently in USA with sponsorship of NCI [37, 38] . This indicates that pharmaceutical researchers still have not lost hope for mithramycin, to be used as a drug candidate in future.
Although from the beginning mithramycin had always been presented as an antitumor drug candidate, as described in Introduction section, recently it has also been proposed as a potential candidate for developing new therapeutic drugs for various other disorders. Similarly, we endeavored to exploit mithramycin for anti-MRSA and anti-VRE activity. Extensive STN (Scientific and Technical Information Network) and other Development of a drug as an antibiotic needs mode of action studies along with in vivo susceptibility data. At present outcome of such studies for mithramycin cannot be predicted. However, considering the ever increasing cost of new drug discovery program all over the world, reports of challenges faced by Linezolid [20] and Daptomycin [21] and over all the grave problem of resistance of staphylococci and enterococci to these established drugs [16] , this study can make scientists revisit the use of mithramycin scaffold, despite its toxicity and side effects.
As confirmed by In vitro studies, mithramycin has potent antibacterial activity. This may be one of the important multiple factors, facilitating dose reduction, required for treating infected animals as compared to high dose regimen of the compound required for the treatment of cancer. Moreover, cancer treatment being a long term process, frequency of occurrence of unpleasant side effects of mithramycin is much more. In contrast, treatment for infectious diseases can be completed in limited period of time and toxic side effects of mithramycin can be minimized considerably.
Recently Nunez et al. [39] reported novel mithramycin analogue (demycarosyl-3D-β-d-digitoxosylmithramycin SK) with high antitumor activity and less toxicity. So alternatively, mithramycin can be used as a 'much needed potential scaffold' for synthesis of less toxic analogs which can also act as anti-MRSA drugs. As mithramycin is a known compound, the time and money required for new drug development in infectious disease area can be reduced substantially and in future mithramycin and its analogs would be new leads for the treatment of variety of Gram positive infectious diseases, associated with resistant strains of MRSA and VRE.
In conclusion, mithramycin obtained from Streptomyces sp. PM1129877, isolated from playa region of Thar Desert in Rajasthan, India, was purified and identified using spectroscopic methods. MIC estimations revealed that mithramycin exhibited anti-MRSA and anti-VRE activity, which was very potent compared to Linezolid. As regimen for infectious disease can be of limited period as compared to lengthy cancer treatment, authors propose and hope that in future mithramycin and its analogs could be potential candidates for developing a suitable lead for treatment of such diseases.
